Literature DB >> 21104407

Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures.

Bernie M McGowan1, Kath Bennett, Joe Marry, J B Walsh, Miriam C Casey.   

Abstract

PURPOSE: We examined the prescribing of antiosteoporotic medications pre- and post hospital admission in patients with fragility fractures as well as factors associated with prescribing of these treatments following admission.
METHODS: We identified all patients aged ≥ 55 years at a large teaching hospital between 2005 and 2008 with a fracture using the Hospital In-Patient Enquiry (HIPE) system. These data were linked to prescribing data from the Health Service Executive Primary Care Reimbursement Services (HSE-PCRS) scheme before and after discharge (821 patients). Logistic regression analysis was used to examine the likelihood of prescription of antiosteoporotic medication pre- and post discharge in relation to year of discharge, age, gender, and type of fracture.
RESULTS: Prescribing of antiosteoporotic treatment before fracture increased from 2.6% [95% confidence interval (CI) 2.23-2.93%] in 2005 to 10.6% (95% CI 9.32-11.86) by 2008, whereas post fracture prescribing increased from 11% (95% CI 9.64-12.36) to 47% (95% CI 43.6-50.3). In patients discharged from hospital in 2007, postfracture prescribing was 31.8% (95% CI 28.66-35.02) at 12 months, increasing to 50.3% (95% CI 46.6-53.9) at 24 months. The highest rate of prescribing was in the 65- to 69-year age group [odds ratio (OR) 8.51, 95% CI 1.75-41.35]. Patients discharged in 2008 were eight times more likely to be treated than patients discharged in 2005 (OR 8.01, 95% CI 4.55-14.09).
CONCLUSION: The percentage of patients on antiosteoporotic treatment post fracture increased significantly from 2005 to 2008. This may be largely due to the introduction of the Osteoporosis Clinic to the hospital in 2005.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104407     DOI: 10.1007/s00228-010-0942-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors:  Angela M Cheung; Denice S Feig; Moira Kapral; Natalia Diaz-Granados; Sylvie Dodin
Journal:  CMAJ       Date:  2004-05-25       Impact factor: 8.262

2.  How well are community-living women treated for osteoporosis after hip fracture?

Authors:  S Bellantonio; R Fortinsky; K Prestwood
Journal:  J Am Geriatr Soc       Date:  2001-09       Impact factor: 5.562

3.  Osteoporosis follow-up after wrist fractures following minor trauma.

Authors:  S A Khan; C de Geus; B Holroyd; A S Russell
Journal:  Arch Intern Med       Date:  2001-05-28

4.  Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures.

Authors:  H Castel; D Y Bonneh; M Sherf; Y Liel
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

5.  Osteoporosis intervention following distal forearm fractures: a missed opportunity?

Authors:  Maria-Teresa Cuddihy; Sherine E Gabriel; Cynthia S Crowson; Elizabeth J Atkinson; Claudia Tabini; W Michael O'Fallon; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-02-25

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

Review 7.  Diagnosis, screening, prevention, and treatment of osteoporosis.

Authors:  Karen F Mauck; Bart L Clarke
Journal:  Mayo Clin Proc       Date:  2006-05       Impact factor: 7.616

Review 8.  Update of current therapeutic options for the treatment of postmenopausal osteoporosis.

Authors:  Solomon Epstein
Journal:  Clin Ther       Date:  2006-02       Impact factor: 3.393

9.  Occurrence and incidence of the second hip fracture.

Authors:  H M Schrøder; K K Petersen; M Erlandsen
Journal:  Clin Orthop Relat Res       Date:  1993-04       Impact factor: 4.176

10.  Secondary prevention of fragility fractures by orthopaedic teams in the UK: a national survey.

Authors:  J Chakravarthy; A Ali; S Iyengar; K Porter
Journal:  Int J Clin Pract       Date:  2008-01-08       Impact factor: 2.503

View more
  3 in total

1.  Disparities in osteoporosis treatments.

Authors:  Z Liu; J Weaver; A de Papp; Z Li; J Martin; K Allen; S Hui; E A Imel
Journal:  Osteoporos Int       Date:  2015-07-28       Impact factor: 4.507

2.  "Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study".

Authors:  Aina Pagès-Castellà; Cristina Carbonell-Abella; Francesc Fina Avilés; Maite Alzamora; Jose Miguel Baena-Díez; Daniel Martínez Laguna; Xavier Nogués; Adolfo Díez-Pérez; Daniel Prieto-Alhambra
Journal:  BMC Musculoskelet Disord       Date:  2012-05-28       Impact factor: 2.362

3.  Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.

Authors:  A Wilk; S Sajjan; A Modi; C-P S Fan; P Mavros
Journal:  Osteoporos Int       Date:  2014-08-12       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.